EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE

每日一次蛋白酶 INHBTR 的功效评估

• 批准号: 7719467
• 负责人: THOMAS A CAMPBELL
• 金额: $ 1.93万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719467
• 关键词: Anti-Retroviral Agents; Antiviral Agents; Computer Retrieval of Information on Scientific Projects Database; Endopeptidases; Funding; Grant; HIV-1; Institution; Label; Nucleosides; Participant; Peptide Hydrolases; Phase; Protease Inhibitor; Randomized; Research; Research Personnel; Resources; Reverse Transcriptase Inhibitors; Source; Treatment Protocols; United States National Institutes of Health; Upper arm; day; design; efficacy trial; non-nucleoside reverse transcriptase inhibitors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5175 is a phase IV, randomized, open-label, three-arm antiviral efficacy trial designed to evaluate three antiretroviral (ARV) regimens for treatment na¿ve HIV-infected participants: one regimen containing two nucleoside reverse transcriptase inhibitors (NRTIs) + an HIV-1 protease inhibitor (PI) regimen, and two regimens each containing two NRTIs + a non-nucleoside reverse transcriptase inhibitor (NNRTI).

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5175是一项IV期、随机、开放标签、三组抗病毒疗效试验，旨在评估三种抗逆转录病毒（ARV）方案对初治HIV感染受试者的疗效：一种方案包含两种核苷类逆转录酶抑制剂（NRTI）+一种HIV-1蛋白酶抑制剂（PI）方案，两种方案各包含两种NRTI+一种非核苷类逆转录酶抑制剂（NNRTI）。